Immuneering (IMRX) Stock Price, News & Analysis

Company Overview

Immuneering (Nasdaq: IMRX) is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering’s machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company’s AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.

The company’s lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy. Immuneering also maintains discovery- and preclinical-stage programs targeting inflammatory and immuno-oncology indications. Through strategic collaborations and licensing partnerships, the company extends the application of its computational platform across multiple therapeutic areas and works alongside pharmaceutical partners to co-develop novel treatments.

Founded in 2016, Immuneering is headquartered in Cambridge, Massachusetts, and operates research facilities in the United States. After completing its initial public offering on the Nasdaq in early 2021, the company has continued to expand its computational infrastructure, diversify its pipeline through in-house research and external collaborations, and advance its mission to bring more effective, AI-driven therapies to patients worldwide.

Key Stats

• Today's Range: $4.69 to $4.84
• 50-Day Range: $4.05 to $5.53
• 52-Week Range: $3.86 to $10.08
• Volume: 323,462 shs
• Average Volume: 1.33 million shs
• Market Capitalization: $308.94 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $17.50
• Consensus Rating: Buy

Immuneering Stock Analysis - MarketRank™

Immuneering scored higher than 59% of companies evaluated by MarketBeat, and ranked 345th out of 906 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.5 / 5
• Analyst Rating: Buy

Consensus Rating

Immuneering has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 strong buy ratings, 4 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Immuneering has a consensus price target of $17.50, representing about 263.1% upside from its current price of $4.82.

Amount of Analyst Coverage

Immuneering has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Immuneering are expected to decrease in the coming year, from ($1.09) to ($1.40) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Immuneering is -4.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Immuneering is -4.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Immuneering has a P/B Ratio of 1.43. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

26.20% of the float of Immuneering has been sold short.

Short Interest Ratio / Days to Cover

Immuneering has a short interest ratio ("days to cover") of 19.36, which indicates bearish sentiment.

Change versus previous month

Short interest in Immuneering has recently decreased by 6.33%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Immuneering does not currently pay a dividend.

Dividend Growth

Immuneering does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Immuneering this week, compared to 3 articles on an average week.

Search Interest

3 people have searched for IMRX on MarketBeat in the last 30 days.

MarketBeat Follows

Only 2 people have added Immuneering to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 3.4 / 5
• Insider Trading: Acquiring Shares

Net Insider Buying

Over the last three months, insiders have purchased a net $10,944.00 in company stock, which represents 0.0035% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Immuneering insiders have bought more of their company's stock than they have sold. Specifically, they have bought $10,944.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

14.90% of the stock of Immuneering is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

67.65% of the stock of Immuneering is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/05/2026
• Today: 9/08/2026
• 12th Annual Cantor Fitzgerald Global Healthcare Conference: 9/10/2026
• H.C. Wainwright 28th Annual Global Investment Conference: 9/14/2026
• Next Earnings (Estimated): 11/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:IMRX
• CIK: 1790340
• Web: www.immuneering.com
• Phone: 617-500-8080
• Fax: N/A
• Employees: 60
• Year Founded: 2008

Price Target and Rating

• Average Price Target for Immuneering: $17.50
• High Price Target: $30.00
• Low Price Target: $12.00
• Potential Upside/Downside: +268.0%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.04)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$56.03 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -27.15%
• Return on Assets: -25.75%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 19.47
• Quick Ratio: 19.47

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.38 per share
• Price / Book: 1.41

Miscellaneous

• Outstanding Shares: 64,700,000
• Free Float: 55,057,000
• Market Cap: $307.65 million
• Optionable: Not Optionable
• Beta: 0.40